- Home
- FRHC vs ROIV Comparison
FRHC vs ROIV Comparison
Compare FRHC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRHC | ROIV |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 28.7B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FRHC | ROIV |
|---|---|---|
| Price | $173.41 | $35.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $48.08 |
| AVG Volume (30 Days) | 49.0K | ★ 6.9M |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.29 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $2,191,291,000.00 | $8,260,000.00 |
| Revenue This Year | N/A | $530.75 |
| Revenue Next Year | N/A | $685.92 |
| P/E Ratio | $329.96 | ★ N/A |
| Revenue Growth | ★ 6.86 | N/A |
| 52 Week Low | $107.98 | $15.25 |
| 52 Week High | $178.00 | $42.50 |
Technical Indicators
Market Signals| Indicator | FRHC | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 46.25 |
| Support Level | $145.61 | $33.15 |
| Resistance Level | $174.21 | $37.59 |
| Average True Range (ATR) | 4.91 | 1.21 |
| MACD | -0.39 | -0.40 |
| Stochastic Oscillator | 43.05 | 22.31 |
Price Performance
Historical ComparisonAbout FRHC Freedom Holding Corp.
Freedom Holding Corp is a holding company with reportable segments into the following four segments: Brokerage, Banking, Insurance, and Other. The majority of revenue is from the Banking segment. Banking segment consists of the operations of Freedom Bank KZ and Freedom Bank TJ. Geographically, operates in Kazakhstan, Armenia, Cyprus, the USA, and others, with maximum revenue from Kazakhstan.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.